Indal

Indalo Therapeutics is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for the treatment of serious fibrotic diseases. Formed through the merger of Antegrin Therapeutics and Cascadia Therapeutics, the company leverages expertise in RGD-binding integrin biology to address unmet needs in conditions such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its lead candidate, IDL-2965, is a potent and selective oral antagonist of integrins αvβ1, αvβ3, and αvβ6, designed to inhibit the activation of TGF-β, a master regulator of fibrosis. By targeting multiple integrin subtypes, Indalo aims to provide a comprehensive anti-fibrotic effect across various organ systems. The company is backed by prominent life science investors and is headquartered in St. Louis, Missouri.